After years of development, SIP has fostered distinct advantages in the biomedical and healthcare sectors, which provides great room for the development of bio-manufacturing.
Bio-manufacturing technology is widely applied in the R&D and innovation processes of biopharmaceutical enterprises, contributing to the development of a wide variety of products such as live biotherapeutic products, novel vaccines, testing and diagnosis products, and cell and gene therapies in SIP.
Notably, bio-manufacturing through synthetic biology approaches is widely used downstream the pharmaceutical industry, expected to alter the landscape of drug research and production modes.
SIP has laid a solid foundation for the development of bio-manufacturing. It has gathered more than 2,000 companies engaged in biomedicine and healthcare, with last year’s output value reaching RMB165.5 billion and a large variety of products under development or marketing. Moreover, it has enhanced policy support for these industries.
August 27, 2025
